AR073111A2 - La preparacion oral solida farmaceutica conteniendo cristales de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma - Google Patents

La preparacion oral solida farmaceutica conteniendo cristales de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma

Info

Publication number
AR073111A2
AR073111A2 ARP090103228A ARP090103228A AR073111A2 AR 073111 A2 AR073111 A2 AR 073111A2 AR P090103228 A ARP090103228 A AR P090103228A AR P090103228 A ARP090103228 A AR P090103228A AR 073111 A2 AR073111 A2 AR 073111A2
Authority
AR
Argentina
Prior art keywords
preparation
minutes
oral preparation
aripiprazol
same
Prior art date
Application number
ARP090103228A
Other languages
English (en)
Inventor
Junichi Kawasaki
Kiyoshi Fujimoto
Koichi Shinhama
Satoshi Aoki
Tsuyoshi Yabuuchi
Yoshihiro Oi
Takuji Bando
Makoto Ishigami
Youichi Taniguchi
Noriyuki Kobayashi
Tsutomu Fujimura
Masanori Takahashi
Kaoru Abe
Shohei Yamada
Michiaki Tominaga
Naoto Utsumi
Yoshihiro Nishioka
Tomonori Nakagawa
Kenji Tomikawa
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36049773&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR073111(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from CA 2379005 external-priority patent/CA2379005A1/en
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of AR073111A2 publication Critical patent/AR073111A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Anesthesiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La preparacion oral solida farmacéutica que es preparada por el proceso que comprende la granulacion humeda de cristales convencionales de Aripiprazol anhidro, el secado de los gránulos obtenidos a 70-100°C y la clasificacion de los mismos segun tamano, luego nuevo secado de los gránulos clasificados a 70-100°C donde dicha preparacion oral solida farmacéutica tiene al menos una velocidad de disolucion seleccionada del grupo que consiste en el 60 % o más con un pH 4,5 luego de 30 minutos, el 70 % o más con un pH 4,5 luego de 60 minutos, y el 55 % o más con un pH 5,0 luego de 60 minutos. La preparacion oral solida farmacéutica que es preparada por el proceso que comprende la granulacion humeda de cristales de hidrato de Aripiprazol convencionales, el secado de los gránulos obtenidos a 70-100°C y la clasificacion de los mismos segun tamano, luego nuevo secado de los gránulos clasificados a 70-100°C donde dicha preparacion oral solida farmacéutica tiene al menos una velocidad de disolucion seleccionada del grupo que consiste en el 60 % o más con un pH 4,5 luego de 30 minutos, el 70 % o más con un pH 4,5 luego de 60 minutos, y el 55 % o más con un pH 5,0 luego de 60 minutos.
ARP090103228A 2001-09-25 2009-08-21 La preparacion oral solida farmaceutica conteniendo cristales de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma AR073111A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001290645 2001-09-25
JP2001348276 2001-11-14
CA 2379005 CA2379005A1 (en) 2001-09-25 2002-03-27 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof

Publications (1)

Publication Number Publication Date
AR073111A2 true AR073111A2 (es) 2010-10-13

Family

ID=36049773

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP090103228A AR073111A2 (es) 2001-09-25 2009-08-21 La preparacion oral solida farmaceutica conteniendo cristales de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
ARP100102387A AR077635A2 (es) 2001-09-25 2010-07-05 Hidrato a de aripiprazol
ARP120102986A AR087544A2 (es) 2001-09-25 2012-08-15 Cristales de aripiprazol anhidro b

Family Applications After (2)

Application Number Title Priority Date Filing Date
ARP100102387A AR077635A2 (es) 2001-09-25 2010-07-05 Hidrato a de aripiprazol
ARP120102986A AR087544A2 (es) 2001-09-25 2012-08-15 Cristales de aripiprazol anhidro b

Country Status (21)

Country Link
EP (1) EP3081216A1 (es)
KR (2) KR100490222B1 (es)
CN (12) CN103755632B (es)
AR (3) AR073111A2 (es)
CA (1) CA2713466C (es)
CL (1) CL2010000405A1 (es)
CY (4) CY1110070T1 (es)
DK (1) DK1925308T3 (es)
ES (1) ES2596354T3 (es)
HK (5) HK1223043A1 (es)
IL (3) IL204707A (es)
LT (1) LT1925308T (es)
MY (1) MY138669A (es)
NO (1) NO337844B1 (es)
PE (1) PE20030445A1 (es)
PH (1) PH12014500782A1 (es)
PL (7) PL219565B1 (es)
PT (1) PT1925308T (es)
RU (1) RU2279429C2 (es)
SI (1) SI1927357T1 (es)
TW (2) TWI318572B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0415531B8 (pt) * 2003-10-23 2021-05-25 Otsuka Pharma Co Ltd formulação de aripiprazol injetável estéril de liberação controlada e método para a sua preparação
JOP20200109A1 (ar) * 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
KR102128883B1 (ko) * 2019-10-02 2020-07-01 (주)삼화바이오팜 고순도 아리피프라졸의 신규 결정형 및 이의 제조방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54130587A (en) * 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JP2608788B2 (ja) 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
JP3638447B2 (ja) * 1998-09-10 2005-04-13 積水ハウス株式会社 笠木取付金具および笠木取付構造
GB9930061D0 (en) * 1999-12-20 2000-02-09 Glaxo Group Ltd Quinolone compounds for use in treating viral infections
EP1818326A1 (en) * 2000-01-20 2007-08-15 Eisai R&D Management Co., Ltd. Nitrogen-containing heterocyclic compounds and pharmaceutical composition containing the compounds
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
WO2003030868A1 (en) * 2001-10-09 2003-04-17 Bristol-Myers Squibb Company Flashmelt oral dosage formulation
JP4197088B2 (ja) 2000-06-05 2008-12-17 電気化学工業株式会社 低密度かつ低ガス透過性六方晶窒化硼素焼結体及びその製造方法
JP2002193915A (ja) * 2000-12-28 2002-07-10 Otsuka Pharmaceut Co Ltd ベンゼンスルフォナート化合物

Also Published As

Publication number Publication date
SI1927357T1 (sl) 2010-09-30
CN103755632B (zh) 2016-06-29
IL225902A0 (en) 2013-06-27
HK1215397A1 (zh) 2016-08-26
TWI332839B (en) 2010-11-11
IL204707A (en) 2016-06-30
CY1110070T1 (el) 2015-01-14
CY1110208T1 (el) 2015-01-14
PL417178A1 (pl) 2016-07-04
CN103751119A (zh) 2014-04-30
PL221521B1 (pl) 2016-04-29
HK1129891A1 (en) 2009-12-11
HK1196128A1 (zh) 2014-12-05
KR100490222B1 (ko) 2005-05-18
HK1203060A1 (en) 2015-10-16
CY1110244T1 (el) 2015-01-14
PL219565B1 (pl) 2015-05-29
PL393603A1 (pl) 2011-04-26
HK1203059A1 (en) 2015-10-16
PL393596A1 (pl) 2011-04-26
LT1925308T (lt) 2016-11-10
RU2004126636A (ru) 2006-02-10
ES2596354T3 (es) 2017-01-09
HK1136959A1 (en) 2010-07-16
HK1092808A1 (en) 2007-02-16
NO337844B1 (no) 2016-06-27
KR100530731B1 (ko) 2005-11-23
CA2713466C (en) 2012-01-03
CN103751118A (zh) 2014-04-30
PH12014500782A1 (en) 2018-09-10
HK1136960A1 (en) 2010-07-16
PE20030445A1 (es) 2003-07-26
RU2279429C2 (ru) 2006-07-10
KR20040053372A (ko) 2004-06-23
CL2010000405A1 (es) 2010-10-15
CN103755632A (zh) 2014-04-30
CN105832677A (zh) 2016-08-10
PT1925308T (pt) 2016-10-24
CN103288727A (zh) 2013-09-11
HK1136958A1 (en) 2010-07-16
PL393601A1 (pl) 2011-04-26
TW200942238A (en) 2009-10-16
HK1136961A1 (en) 2010-07-16
NO20141193L (no) 2003-01-17
MY138669A (en) 2009-07-31
KR20030060871A (ko) 2003-07-16
CN105267151A (zh) 2016-01-27
IL234770A0 (en) 2014-11-30
HK1223043A1 (zh) 2017-07-21
HK1187048A1 (zh) 2014-03-28
PL219564B1 (pl) 2015-05-29
TWI318572B (en) 2009-12-21
HK1129889A1 (en) 2009-12-11
EP3081216A1 (en) 2016-10-19
PL393607A1 (pl) 2011-03-14
HK1210468A1 (en) 2016-04-22
CY1110212T1 (el) 2015-01-14
CN103751093A (zh) 2014-04-30
CN102579446A (zh) 2012-07-18
PL393608A1 (pl) 2011-03-14
PL221536B1 (pl) 2016-04-29
AR087544A2 (es) 2014-04-03
PL230869B1 (pl) 2018-12-31
IL204707A0 (en) 2010-11-30
DK1925308T3 (en) 2016-12-12
CA2713466A1 (en) 2003-04-03
CN103288727B (zh) 2016-04-27
CN104945321A (zh) 2015-09-30
CN104306337A (zh) 2015-01-28
CN104306374A (zh) 2015-01-28
CN103191118A (zh) 2013-07-10
AR077635A2 (es) 2011-09-14
PL393598A1 (pl) 2011-04-26

Similar Documents

Publication Publication Date Title
PE20090124A1 (es) Composicion farmaceutica que comprende cristales de aripiprazol b de baja higroscopicidad y procedimiento de preparacion de la misma
BR9713199A (pt) Péletes de desintegração rápida
BRPI0712101B8 (pt) ácido beta-fenil-alfa-hidróxi propanóico substituído, método de síntese e uso do mesmo
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
CL2004000782A1 (es) Composicion farmaceutica parenteral que comprende (a) piperacilina, (b) tazobactamo, y un acido aminocarboxilico quelante, que ademas puede contener un tampon, como citrato, y opcionalmente un aminoglicosido; procedimientos para su preparacion; y uso
NO20072918L (no) Heteroaromatiske quinolinforbindelser, og anvendelse av disse som inhibitorer av PDE10
BRPI0307351B8 (pt) composto, composição farmacêutica, uso de um composto, e, processo para preparar um composto
NO20033181L (no) Substituerte alkylaminderivater og fremgangsmåter for anvendelse
DE60122767D1 (de) Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
HRP20090194T1 (hr) Suha granulirana kompozicija koja sadrži emtricitabin i tenofovir df
BR0316091A (pt) Compostos, processo para a manufatura dos mesmos, composições farmacêuticas, método para o tratamento e/ou prevenção de enfermidades que são moduladas por agonistas ppar(a) e/ou ppar(y) e/ou utilização dos mesmos
BRPI0514133A (pt) compostos de fórmula i, processo para a sua fabricação, composições farmacêuticas, método para o tratamento e/ou profilaxia de doença que são mediadas por inibidores de cetp e uso dos compostos de fórmula i
BR0315808A (pt) Composições biocìdicas aquosa e sólida contendo bromo ativo e processo de produção destas
ECSP055584A (es) Proceso para la preparación de fibrinógeno
BR9607189A (pt) Formas de dosagem oral contendo um antibiótico de b-lactama
EA200702589A1 (ru) 2,6-хинолинильные производные, способы их получения и их применение
BR0213878A (pt) Processo para a formação de sólidos de ibuprofeno
PT1326502E (pt) Processo para a producao de uma mistura apta a ser granulada e hidroxicitrato de carnitina e magnesio
AR033863A1 (es) Una composicion de blanqueo con aire, que tiene mejoradas propiedades de almacenamiento, y un procedimiento para preparar dicha composicion
CL2010000405A1 (es) Procesos para preparar una composicion farmaceutica oral solida que contiene granulos de aripiprazol, de baja higroscopicidad (sol. div. 2217-02).
UY27399A1 (es) Proceso para la preparación de quinazolinas
BRPI0416284A (pt) compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os contêm, método para o tratamento e/ou prevenção de enfermidades que são moduladas por agonistas ppar(delta) e/ou ppar(alfa) e sua utilização
BR0314838A (pt) Sistema de liberação controlada, e, processo para preparar comprimidos de liberação controlada de temozolomida
IS7200A (is) Notkun á írbesartan til framleiðslu á lækningalyfjum sem notuð eru til að koma í veg fyrir eða meðhöndla lungnaháþrýsting
EA200300448A1 (ru) Композиции, включающие соединения модафинила

Legal Events

Date Code Title Description
FC Refusal